A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency

  1. Baptiste Fouquet
  2. Patrycja Pawlikowska
  3. Sandrine Caburet
  4. Celine Guigon
  5. Marika Mäkinen
  6. Laura Tanner
  7. Marja Hietala
  8. Kaja Urbanska
  9. Laura Bellutti
  10. Bérangère Legois
  11. Bettina Bessieres
  12. Alain Gougeon
  13. Alexandra Benachi
  14. Gabriel Livera
  15. Filippo Rosselli
  16. Reiner A Veitia
  17. Micheline Misrahi  Is a corresponding author
  1. Faculté de médecine Paris Sud, France
  2. Université Paris Sud, France
  3. Université Paris Diderot, France
  4. Turku University Hospital, Finland
  5. Hôpital Necker-enfants malades, APHP, France
  6. Faculté de Médecine Laennec, France

Abstract

Primary Ovarian Insufficiency (POI) affects ~1% of women under forty. Exome sequencing of two Finnish sisters with non-syndromic POI revealed a homozygous mutation in FANCM, leading to a truncated protein (p.Gln1701*). FANCM is a DNA-damage response gene whose heterozygous mutations predispose to breast cancer. Compared to the mother's cells, the patients' lymphocytes displayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities. Their lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was impaired. Genetic complementation of patient's cells with wild-type FANCM improved their resistance to MMC re-establishing FANCD2 monoubiquitinationFANCM was more strongly expressed in human fetal germ cells than in somatic cells. FANCM protein was preferentially expressed along the chromosomes in pachytene cells, which undergo meiotic recombination. This mutation may provoke meiotic defects leading to a depleted follicular stock, as in Fancm-/- mice. Our findings document the first Mendelian phenotype due to a biallelic FANCM mutation.

Article and author information

Author details

  1. Baptiste Fouquet

    Hopital Bicetre, Faculté de médecine Paris Sud, Le Kremlin Bicetre, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Patrycja Pawlikowska

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Sandrine Caburet

    Molecular Oncology and Ovarian Pathologies, Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7404-8213
  4. Celine Guigon

    CNRS, UMR 8251, INSERM, U1133, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Marika Mäkinen

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  6. Laura Tanner

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  7. Marja Hietala

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  8. Kaja Urbanska

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Laura Bellutti

    UMR967 INSERM, CEA/DRF/iRCM/SCSR/LDG, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Bérangère Legois

    Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Bettina Bessieres

    Department of Histology, Embryology and Cytogenetics, Hôpital Necker-enfants malades, APHP, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Alain Gougeon

    UMR Inserm 1052, CNRS 5286, Faculté de Médecine Laennec, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Alexandra Benachi

    Department of Obstetrics and Gynaecology, Université Paris Sud, Clamart, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Gabriel Livera

    UMR967 INSERM, CEA/DRF/iRCM/SCSR/LDG, Université Paris Diderot, Fontenay aux Roses, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Filippo Rosselli

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Reiner A Veitia

    Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Micheline Misrahi

    Hopital Bicetre, Faculté de médecine Paris Sud, Le Kremlin Bicetre, France
    For correspondence
    Micheline.misrahi@aphp.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5379-8859

Funding

Fondation pour la Recherche Médicale (DEQ20150331757)

  • Baptiste Fouquet
  • Sandrine Caburet
  • Reiner A Veitia
  • Micheline Misrahi

Ligue Contre le Cancer

  • Patrycja Pawlikowska
  • Filippo Rosselli

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Andrew Deans, St Vincent's Institute of Medical Research, Australia

Ethics

Human subjects: The study was approved by all the institutions involved. All participants gave informed consent for the study and the study was approved by the agence de Biomedecine (reference number PFS12-002).

Version history

  1. Received: July 18, 2017
  2. Accepted: December 11, 2017
  3. Accepted Manuscript published: December 12, 2017 (version 1)
  4. Version of Record published: January 11, 2018 (version 2)

Copyright

© 2017, Fouquet et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,398
    Page views
  • 392
    Downloads
  • 57
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Baptiste Fouquet
  2. Patrycja Pawlikowska
  3. Sandrine Caburet
  4. Celine Guigon
  5. Marika Mäkinen
  6. Laura Tanner
  7. Marja Hietala
  8. Kaja Urbanska
  9. Laura Bellutti
  10. Bérangère Legois
  11. Bettina Bessieres
  12. Alain Gougeon
  13. Alexandra Benachi
  14. Gabriel Livera
  15. Filippo Rosselli
  16. Reiner A Veitia
  17. Micheline Misrahi
(2017)
A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency
eLife 6:e30490.
https://doi.org/10.7554/eLife.30490

Share this article

https://doi.org/10.7554/eLife.30490

Further reading

    1. Biochemistry and Chemical Biology
    2. Medicine
    Giulia Leanza, Francesca Cannata ... Nicola Napoli
    Research Article

    Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral density. We reported that bone formation genes (SOST and RUNX2) and advanced glycation end-products (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D (T2D 0.249% [0.156–0.366]) vs non-diabetic subjects 0.352% [0.269–0.454]; p=0.053, as well as reduced bone strength (T2D 21.60 MPa [13.46–30.10] vs non-diabetic subjects 76.24 MPa [26.81–132.9]; p=0.002). We also showed that gene expression of Wnt agonists LEF-1 (p=0.0136) and WNT10B (p=0.0302) were lower in T2D. Conversely, gene expression of WNT5A (p=0.0232), SOST (p<0.0001), and GSK3B (p=0.0456) were higher, while collagen (COL1A1) was lower in T2D (p=0.0482). AGEs content was associated with SOST and WNT5A (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely correlated with LEF-1 and COL1A1 (r=–0.7500, p=0.0255; r=–0.9762, p=0.0004). SOST was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, p=0.00174), whereas WNT5A and GSK3B were only correlated with glycemic control (r=0.5589, p=0.0037; r=0.4901, p=0.0051). Finally, Young’s modulus was negatively correlated with SOST (r=−0.5675, p=0.0011), AXIN2 (r=−0.5523, p=0.0042), and SFRP5 (r=−0.4442, p=0.0437), while positively correlated with LEF-1 (r=0.4116, p=0.0295) and WNT10B (r=0.6697, p=0.0001). These findings suggest that Wnt signaling and AGEs could be the main determinants of bone fragility in T2D.

    1. Medicine
    Valentina Daponte, Katrin Henke, Hicham Drissi
    Review Article

    Bone remodeling is a complex process involving the coordinated actions of osteoblasts and osteoclasts to maintain bone homeostasis. While the influence of osteoblasts on osteoclast differentiation is well established, the reciprocal regulation of osteoblasts by osteoclasts has long remained enigmatic. In the past few years, a fascinating new role for osteoclasts has been unveiled in promoting bone formation and facilitating osteoblast migration to the remodeling sites through a number of different mechanisms, including the release of factors from the bone matrix following bone resorption and direct cell–cell interactions. Additionally, considerable evidence has shown that osteoclasts can secrete coupling factors known as clastokines, emphasizing the crucial role of these cells in maintaining bone homeostasis. Due to their osteoprotective function, clastokines hold great promise as potential therapeutic targets for bone diseases. However, despite long-standing work to uncover new clastokines and their effect in vivo, more substantial efforts are still required to decipher the mechanisms and pathways behind their activity in order to translate them into therapies. This comprehensive review provides insights into our evolving understanding of the osteoclast function, highlights the significance of clastokines in bone remodeling, and explores their potential as treatments for bone diseases suggesting future directions for the field.